BIOTRICITY INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOTRICITY INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | $398.2K | Jul 16, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $13.79M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $12.06M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $9.64M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $7.65M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $3.38M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $1.42M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $398.2K | Jul 15, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.56M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $8.36M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $5.44M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $4.57M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $1.27M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $485.8K | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $59.9K | Jul 15, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($8.42M) | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | ($14.09M) | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | ($18.66M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($29.13M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($15.49M) | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | ($11.07M) | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | ($8.59M) | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | ($8.62M) | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | ($7.81M) | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | ($7.28M) | Mar 30, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.45M) | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | ($8.83M) | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | ($15.41M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($16.74M) | Jun 29, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.16M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $2.57M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $3.23M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $2.74M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $2.06M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $1.36M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $1.31M | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | $1.76M | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | $1.14M | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | $1.09M | Mar 30, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.86M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $14.61M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $17.62M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $18.56M | Jun 29, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.38M) | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | ($6.69M) | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | ($13.55M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($15.16M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($11.08M) | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | ($7.86M) | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | ($5.22M) | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | ($4.87M) | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | ($3.75M) | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | ($2.38M) | Mar 30, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2022 | $29.8K | Jun 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.64M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $5.94M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $6.51M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $16.68M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $4.44M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $2.00M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $490.7K | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | $929.4K | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | $473.5K | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | $67.5K | Mar 30, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $35.66M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $35.92M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $26.36M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $18.82M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $11.27M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $5.00M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $2.27M | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | $756.2K | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | $4.86M | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | $4.14M | Mar 30, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($32.01M) | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | ($31.47M) | Jul 18, 2025 |
| FY2025 | Mar 31, 2023 | ($19.85M) | Jul 18, 2025 |
| FY2024 | Mar 31, 2022 | ($2.14M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2021 | ($6.83M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2020 | ($3.00M) | Jul 14, 2022 |
| FY2021 | Mar 31, 2019 | ($1.78M) | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | $173.2K | Jul 15, 2020 |
| FY2019 | Mar 31, 2017 | ($4.38M) | Jul 16, 2019 |
| FY2016 | Dec 31, 2016 | ($4.07M) | Mar 30, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($139.44M) | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | ($127.50M) | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | ($112.57M) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | ($93.04M) | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | ($62.82M) | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | ($46.36M) | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | ($35.04M) | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | ($26.45M) | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | ($18.31M) | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | ($16.51M) | Mar 30, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $365.1K | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | $786.1K | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | $570.5K | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | $12.07M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | $2.20M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | $949.8K | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $63.6K | Jul 15, 2020 |
| FY2018 | Mar 31, 2018 | $843.6K | Jul 13, 2018 |
| FY2018 | Mar 31, 2017 | $424.9K | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | $20.7K | Mar 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | (1) | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | (2) | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jul 14, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | (1) | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | (2) | Jun 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 26.08M | Jul 18, 2025 |
| FY2025 | Mar 31, 2024 | 9.35M | Jul 18, 2025 |
| FY2024 | Mar 31, 2023 | 8.51M | Jun 27, 2024 |
| FY2023 | Mar 31, 2022 | 49.81M | Jun 29, 2023 |
| FY2022 | Mar 31, 2021 | 36.12M | Jul 14, 2022 |
| FY2021 | Mar 31, 2020 | 32.59M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | 31.05M | Jul 15, 2020 |
| FY2019 | Mar 31, 2018 | 23.71M | Jul 16, 2019 |
| FY2018 | Mar 31, 2017 | 18.08M | Jul 13, 2018 |
| FY2016 | Dec 31, 2016 | 17.13M | Mar 30, 2017 |